Medincell Aktie [WKN DE: A2N6VA / ISIN: FR0004065605]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Medincell SA Reg S

06.11.24		Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3 (Businesswire)
04.11.24		Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241 (Businesswire)
23.09.24		Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia (Businesswire)
23.09.24		Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris® (Businesswire)
05.09.24		Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) (Businesswire)
03.09.24		Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline (Businesswire)
31.07.24		Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress (Businesswire)
08.05.24		Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia (Businesswire)
16.04.24		Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies (Businesswire)
08.04.24		Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria (Businesswire)
31.01.24		MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI) (Businesswire)
09.01.24		MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI) (Businesswire)
13.11.23		MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749) (Businesswire)
30.08.23		MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement (Businesswire)
04.05.23		MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada) (Businesswire)
24.01.23		Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK) (Businesswire)
05.01.23		MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population (Businesswire)
30.11.22		Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive (Businesswire)
23.11.22		France : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments (Businesswire)
07.11.22		MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement (Businesswire)
13.09.22		MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission (Businesswire)
05.09.22		MedinCell Secures Additional 20 Million Euros Financing With the European Investment Bank (EIB) (Businesswire)
29.08.22		Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology (Businesswire)
17.08.22		An Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report (Businesswire)
09.05.22		MedinCell: US Pharma Development Expert Richard Malamut, MD Becomes Chief Medical Officer (Businesswire)
03.05.22		MedinCell’s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM (Businesswire)
20.04.22		MedinCell provides additional information regarding the new drug application for MDC-IRM (Businesswire)
28.03.22		MedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE (Businesswire)
14.06.21		MedinCell’s Long-Acting Injectable to Fight Malaria Ready to Enter Regulatory Development (Businesswire)
19.04.21		Clinical Trial Conducted by MedinCell Confirms the Safety of Continuous Administration of Ivermectin (Businesswire)
25.03.21		MedinCell: mdc-CWM Clinical Phase 3 Will Start In 2021 (Businesswire)
05.03.21		Covid-19: MedinCell Publishes an Extensive Ivermectin Safety Expert Analysis (Businesswire)
11.02.21		Tremendous success for MedinCell’s €30 million capital increase for qualified investors (Businesswire)
10.02.21		MedinCell Announces a Capital Increase of a c.€30 Million (Businesswire)
17.12.20		Covid-19: MedinCell Presents Positive First Results From the Clinical Trial Aiming at Validating the Safety of Continuous Administration of Ivermectin (Businesswire)
12.11.20		First Long-acting Injectable (LAI) Antipsychotic Using MedinCell’s Technology Reaches Phase 3 Clinical Study Primary Completion Date (Businesswire)
29.09.20		MedinCell Initiates the First Clinical Trial of Its Covid-19 Prevention Program (Businesswire)
16.06.20		MedinCell Announces the Great Success of Its Capital Increase and Raises 15.6 M€ (Businesswire)
15.06.20		MedinCell Launches a Capital Increase of a Minimum of 11 M€ (Businesswire)
10.06.20		MedinCell Successfully Renegotiates the Drawdown Conditions of the Last Tranche of The EIB Loan and Secures an Additional €5m of Non-dilutive Funding (Businesswire)
23.04.20		MedinCell: Adapt and overcome in response to the Covid-19 crisis (Businesswire)
22.04.20		MedinCell launches Regulatory Development of mdc-WWM Program (Businesswire)
06.04.20		MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin (Businesswire)
25.03.20		MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria (Businesswire)
28.01.20		US Pharma Development Veteran Dr. Richard Malamut Joins the Medical Advisory Board of MedinCell (Businesswire)
13.01.20		MedinCell provides a portfolio update for J.P. Morgan Healthcare Conference 2020 (Businesswire)
03.12.19		MedinCell: Publication of the Activity Report and Financial Information for the First Half-year (April - Sept. 2019) (Businesswire)
28.11.19		Medincell Receives $19 Million Grant for Its mdc-WWM Program (Businesswire)
25.09.19		MedinCell Announces That mdc-CWM Progresses as Planned (Businesswire)
04.09.19		MedinCell Receives a New Grant to Develop a Best-in-class Long-acting Injectable Product for HIV PrEP (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 18:55
Kaufwert:	EUR
	Hinzufügen Speichern